Chronic Heart Failure | Reduced Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2019

Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of supporting evidence from clinical trials. ACE inhibitors or AIIRA/ARBs, beta blockers, and loop diuretics are typically used in first-line treatment of HFrEF patients. Given the heavily genericized nature of the market, branded agents, such as Novartis’s Entresto and Amgen’s Corlanor, have had difficulty establishing a foothold; however, use of Entresto has been steadily growing since its launch in 2015. This HFrEF treatment algorithm offers insight into the U.S. prescribing patterns in this CHF subpopulation.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
• How have Entresto and Corlanor been integrated into the treatment algorithm, and what is their source of business?
• What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of HFrEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated HFrEF patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.